PATENT CLAIM ANALYSIS

Application Number: 16094644
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["424", "470000"]

Abstract:
Described herein are pharmaceutical compositions for the oral administration of mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of mesalazine.

Claim (Index 65):
A method of making a unit dose pharmaceutical product according to  claim 42 , comprising:\n (a) forming a plurality of delayed-immediate release minitablets (a); (b) forming a plurality of delayed-extended release minitablets (b); and (c) providing (a) and (b) in a sachet, capsule, or vial, thereby obtaining the unit dose pharmaceutical product, wherein the relative amounts of (a) and (b) in the unit dose pharmaceutical product are such that from 10 to 90% w/w of the mesalazine provided in the unit dose pharmaceutical is present in the delayed-extended release minitablets of (b), and the total amount of mesalazine in the unit dose pharmaceutical product is from about 0.4 to 6 g.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.46429
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15076253', '14255529', '14589839', '14230067', '14841428']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7358870820444672
- 35 USC 102 Novelty (BERT): 0.5168165721028716
- Combined Prediction Score: 0.7139800310503076
- Mean Citation Score: 313.1899160000001
- Max Citation Score: 319.44415
- Similarity Product: 240.9383668943345

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test